U.S. Stock News

Recent leadership changes at Fortune Brands Innovations (FBIN), including interim management following activist investor pressure and a canceled CEO appointment, have put the stock in focus ahead of the Q1 2026 earnings report. See our latest analysis for Fortune Brands Innovations. The leadership turmoil and fresh dividend declaration are playing out against a share price that has fallen around 33% over 90 days and a 1 year total shareholder return of about 15% in decline. Shorter term price...

Axcelis Technologies (ACLS) is approaching a closely watched catalyst, with Q1 2026 results and an earnings call scheduled for May 7. Analysts are focusing on profitability pressures and softer revenue expectations. See our latest analysis for Axcelis Technologies. The stock has been on a sharp upswing, with a 1 month share price return of 75.38% and year to date share price return of 98.56%, while the 1 year total shareholder return is 194.42%. This indicates strong momentum into the Q1 2026...

Lumen Technologies (LUMN) opened Q1 2026 with revenue of US$2.9 billion and a basic EPS loss of US$0.20, alongside net income excluding extra items of a US$200 million loss. Over recent quarters, revenue moved from US$3.3 billion in Q4 2024 to US$3.2 billion in Q1 2025 and US$3.0 billion in Q4 2025. Basic EPS shifted from a profit of US$0.09 in Q4 2024 to losses of US$0.20 in Q1 2025 and US$0.00 in Q4 2025. Taken together, these figures frame Q1 2026 as another period where investors are...

Why Crocs stock is back in focus after mixed earnings and guidance Crocs (CROX) just reported first quarter 2026 results showing lower sales and net income year over year, while at the same time tightening second quarter guidance and raising its full year earnings outlook. The combination of softer recent performance and a more confident full year earnings range is giving investors fresh information on how the company sees demand, profitability and its broader footwear portfolio for the rest...

Flywire (FLYW) has kicked off Q1 2026 with total revenue of US$188.1 million, basic EPS of US$0.10, and trailing twelve month EPS of US$0.24, alongside very large year over year earnings growth and a net profit margin reported at 4.5% versus 1% a year ago. Over recent quarters the company has seen revenue move from US$117.6 million in Q4 2024 to US$133.5 million in Q1 2025, US$131.9 million in Q2 2025, US$200.1 million in Q3 2025, US$157.5 million in Q4 2025, and now US$188.1 million in Q1...

Sarepta Therapeutics (SRPT) stock is reacting to first quarter earnings, where revenue of US$730.8 million compared with US$744.86 million a year earlier, while net income reached US$330.96 million after a prior net loss. See our latest analysis for Sarepta Therapeutics. The latest earnings reversal has arrived after a volatile stretch, with a 90 day share price return of 35.23% and a 1 year total shareholder return decline of 37.28%, suggesting that recent momentum contrasts with longer term...

In the first quarter of 2026, Universal Health Services reported higher revenue of US$4,495.18 million and net income of US$348.68 million, while also repurchasing 675,000 shares for US$127.3 million and arranging up to US$900 million in new credit facilities partly to fund its Talkspace acquisition. This combination of stronger profitability, continued share repurchases, and additional financing capacity suggests management is actively reshaping the company’s capital structure and...

Investors may be wondering whether Ovintiv's share price still offers value after a strong run, or if most of the opportunity is already reflected in the stock. The stock last closed at US$59.90, with returns of 47.9% year to date and 81.8% over the past year. Over the past 7 days the return was a 1.9% decline, and over the past 30 days the return was 0.8%. Recent price moves have drawn attention to how the market is currently weighing Ovintiv's prospects against its risks. Ongoing sector...

BKV Corporation has reported first-quarter 2026 results, with revenue of US$432.85 million versus US$176.07 million a year earlier and net income of US$44.08 million, compared with a net loss of US$81.98 million, alongside a successful equity raise of US$186.2 million. The company’s return to profitability, combined with progress in its power and carbon capture projects and increased ownership in its BKV-BPP Power joint venture, underpins a broader shift toward integrated low‑carbon energy...

KLA (NasdaqGS:KLAC) announced a ten-for-one stock split alongside a 21% increase in its dividend. The company is also positioned to supply inspection and process control equipment to the planned Terafab U.S. chip fabrication project focused on advanced AI processors. These developments are new for KLA and are expected to influence how investors think about the stock and its role in future U.S. chip production. For context, KLA shares recently closed at $1,816.29, with the stock up 17.9%...

Adaptive Biotechnologies (ADPT) opened Q1 2026 with revenue of US$70.9 million and a basic EPS loss of US$0.13, alongside a net loss of US$20.0 million. Over recent quarters the company has seen revenue move from US$47.5 million in Q4 2024 to US$52.4 million in Q1 2025, US$58.9 million in Q2 2025, US$94.0 million in Q3 2025 and US$71.7 million in Q4 2025. Quarterly EPS ranged from a loss of US$0.23 in Q4 2024 to a profit of US$0.06 in Q3 2025 and back to a loss of US$0.09 in Q4 2025, putting...

CNA Financial (CNA) is back in focus after first quarter 2026 results showed softer earnings and an underwriting setback in its core Property & Casualty business, alongside an ongoing cash dividend commitment. See our latest analysis for CNA Financial. The weaker first quarter earnings and underwriting results have coincided with a 7 day share price return of 9.12% and a 90 day share price return of 13.31%. The 3 year total shareholder return of 37.57% suggests momentum has been stronger over...

Genius Sports Limited has reported first-quarter 2026 results, with sales rising to US$187.95 million from US$143.99 million a year earlier, while net loss widened to US$55.47 million and loss per share increased to US$0.21. Alongside these results, Genius Sports has rolled out its GeniusIQ data and AI platform across every Liga MX stadium, positioning its technology at the center of Mexican soccer’s officiating, fan engagement, and sponsorship infrastructure. Next, we’ll explore how Genius...

The RMR Group Inc. has reported past second-quarter 2026 results, with sales rising to US$5.1 million while revenue fell to US$145.63 million, and quarterly net income declining to US$1.01 million, or US$0.05 per diluted share, compared with the prior year period. Over the first six months of fiscal 2026, higher sales but lower revenue coincided with net income improving to US$13.2 million, highlighting a contrast between weaker quarterly profitability and stronger year‑to‑date earnings. We...

Crown Holdings’ recent first-quarter 2026 results showed sales rising to US$3,259 million while net income and earnings per share eased, and the company affirmed a quarterly dividend of US$0.35 per share payable on May 28, 2026. At the same time, Crown announced plans for a new beverage can plant in Northern India capable of producing about 2.20 billion cans annually, supported by long-term customer commitments that underline demand for aluminum packaging. With higher volumes but pressured...

United Airlines Holdings (UAL) stock is back in focus after Q1 2026 results came in ahead of expectations, with management leaning on tighter capacity and pricing to help offset fuel volatility and support margins. See our latest analysis for United Airlines Holdings. The recent 6.8% 1 day and 12.0% 30 day share price returns suggest momentum is rebuilding after a weaker period. The 1 year total shareholder return of 26.0% and 3 year total shareholder return of about 12x indicate longer term...

Moderna published Phase 3 results for its mRNA-1010 flu vaccine in the New England Journal of Medicine. The mRNA flu vaccine showed higher efficacy compared with standard seasonal flu shots. Regulatory filings are in progress in the US, EU, and other regions to seek approval for mRNA-1010. For investors watching NasdaqGS:MRNA, this flu update comes with the stock at $48.79 and a mixed return profile. The share price is up 6.7% over the past week, flat over 30 days, and higher by 58.1% year...

Stock performance and recent context W. R. Berkley (WRB) has seen mixed share performance recently, with the stock near US$66 and returns showing modest movement over the past week and month, but a more pronounced decline over the past 3 months and year. See our latest analysis for W. R. Berkley. Recent trading has been soft, with a 90 day share price return of about a 7% decline and a 1 year total shareholder return of about a 7% decline, even though the 3 and 5 year total shareholder...

Wondering if Robinhood Markets at around US$79 per share is still compelling value or if the easy gains are behind it? This article breaks down what the current price really reflects. The stock has been volatile recently, with an 11% return over the last 7 days, 13.3% over the last 30 days, a 31.4% decline year to date, and a 58.1% return over the last year, which can shift how the market is thinking about both opportunity and risk. Recent coverage has focused on Robinhood's evolving role in...

What recent moves in Veradermics (MANE) might be telling you Veradermics (MANE) has drawn attention after a sharp month return of about 72% and a very large past 3 months move, putting its clinical stage dermatology pipeline and valuation in sharper focus for investors. See our latest analysis for Veradermics. The recent 72% 30 day share price return and very large 90 day move sit alongside a 190.78% year to date share price return, which points to strong upward momentum despite a 4.38% one...

Investors may be wondering whether United Therapeutics at around US$596.76 is still offering value after a strong run, or if the easy gains are already behind it. The stock has recent returns of 4.5% over 7 days, 6.6% over 30 days, 20.1% year to date, 94.4% over 1 year and 181.2% over 3 years. This puts valuation questions front and center for anyone considering it today. Recent coverage has focused on United Therapeutics as a high growth biotech with a strong pipeline and regulatory...

In the past week, Piper Sandler Companies reported first-quarter 2026 revenue of US$475.15 million and net income of US$65.24 million, raised its quarterly dividend to US$0.20 per share, completed a US$61.55 million buyback program, and added healthcare investment banker Patrick McCormack, M.D., as a managing director. Together, the stronger-than-expected revenue, 14% dividend increase, continued share repurchases, and senior healthcare hire highlight management’s focus on shareholder...

Pool Corporation (NasdaqGS:POOL) has announced the immediate departure of CEO Peter D. Arvan. John B. Watwood has been appointed as the new President and CEO, with John E. Stokely becoming Executive Chair. The company has postponed its upcoming Investor Day following the leadership change. Pool enters this leadership transition after a period of weak share price performance, with NasdaqGS:POOL at $188.09 and showing a 10.3% decline over the past week and 35.2% decline over the past year...

Gold Royalty Corp. has reported its first-quarter 2026 results, with sales rising to US$7.18 million and net income reaching US$1.77 million. The shift from a net loss a year earlier to positive earnings per share, alongside ample cash and no debt, highlights a marked improvement in financial flexibility. We'll examine how Gold Royalty's return to profitability and reaffirmed 2026 production outlook may influence its longer-term investment narrative. The future of work is here. Discover the...